Eli Lilly and Co. (NYSE:LLY)‘s stock had its “buy” rating restated by stock analysts at Citigroup Inc. in a report issued on Tuesday.

Several other brokerages also recently weighed in on LLY. Argus raised their target price on shares of Eli Lilly and from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, August 2nd. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $93.00 price objective for the company in a research note on Friday, July 29th. BMO Capital Markets reiterated a “buy” rating and set a $94.00 price objective on shares of Eli Lilly and in a research note on Wednesday, July 27th. Leerink Swann reiterated a “buy” rating and set a $103.00 price objective on shares of Eli Lilly and in a research note on Sunday, October 9th. Finally, Deutsche Bank AG reiterated a “buy” rating on shares of Eli Lilly and in a research note on Tuesday, September 20th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Eli Lilly and currently has a consensus rating of “Buy” and an average target price of $108.95.

Shares of Eli Lilly and (NYSE:LLY) opened at 69.12 on Tuesday. The stock has a market cap of $73.11 billion, a price-to-earnings ratio of 30.07 and a beta of 0.28. The firm has a 50-day moving average price of $76.69 and a 200-day moving average price of $77.92. Eli Lilly and has a 52 week low of $64.18 and a 52 week high of $88.16.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, October 25th. The company reported $0.88 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.96 by $0.08. The firm earned $5.19 billion during the quarter, compared to analyst estimates of $4.23 billion. Eli Lilly and had a net margin of 11.73% and a return on equity of 23.71%. Eli Lilly and’s revenue was up 4.7% on a year-over-year basis. During the same quarter last year, the business earned $0.89 earnings per share. On average, equities analysts anticipate that Eli Lilly and will post $3.55 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 9th. Stockholders of record on Tuesday, November 15th will be paid a dividend of $0.51 per share. The ex-dividend date is Thursday, November 10th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 2.95%. Eli Lilly and’s dividend payout ratio is currently 88.70%.

In other news, insider Maria A. Crowe sold 2,248 shares of the business’s stock in a transaction dated Wednesday, October 5th. The shares were sold at an average price of $81.37, for a total transaction of $182,919.76. Following the completion of the sale, the insider now owns 94,319 shares of the company’s stock, valued at $7,674,737.03. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.20% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Mizuho Trust & Banking Co. Ltd. boosted its stake in Eli Lilly and by 0.6% in the second quarter. Mizuho Trust & Banking Co. Ltd. now owns 1,625,795 shares of the company’s stock worth $128,031,000 after buying an additional 10,250 shares in the last quarter. Mason Street Advisors LLC acquired a new position in Eli Lilly and during the second quarter worth $10,304,000. RNC Capital Management LLC raised its position in Eli Lilly and by 42.4% in the second quarter. RNC Capital Management LLC now owns 410,784 shares of the company’s stock worth $32,349,000 after buying an additional 122,237 shares during the last quarter. Zacks Investment Management raised its position in Eli Lilly and by 2.5% in the second quarter. Zacks Investment Management now owns 186,823 shares of the company’s stock worth $14,712,000 after buying an additional 4,585 shares during the last quarter. Finally, Private Capital Advisors Inc. acquired a new position in Eli Lilly and during the second quarter worth $28,535,000. 75.11% of the stock is owned by institutional investors and hedge funds.